US 12,391,753 B2
Antigen binding molecule formats
Tong Zhang, New Rochelle, NY (US); Samuel Davis, New York, NY (US); Chia-Yang Lin, Scarsdale, NY (US); Eric Smith, New York, NY (US); Erica Pyles, New City, NY (US); Michael Rosconi, New City, NY (US); Nina Liu, Chappaqua, NY (US); Supriya Patel, Elmsford, NY (US); and Andrew J. Murphy, Croton-on-Hudson, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Dec. 11, 2024, as Appl. No. 18/977,144.
Application 18/977,144 is a continuation of application No. 16/987,487, filed on Aug. 7, 2020, granted, now 12,215,148.
Claims priority of provisional application 63/050,483, filed on Jul. 10, 2020.
Claims priority of provisional application 62/884,496, filed on Aug. 8, 2019.
Prior Publication US 2025/0109194 A1, Apr. 3, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 39/395 (2013.01); A61K 47/6845 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 16/46 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 22 Claims
 
1. An antigen-binding molecule comprising:
(a) a first half antibody comprising in an N- to C-terminal orientation:
(i) a first Fc domain which lacks a Fab domain at its N-terminus; and
(ii) a first Fab domain that binds to a target molecule having a molecular weight of less than 100 kDa exclusive of post-translational modifications, the first Fab domain comprising a first heavy chain variable region (VH) associated with a first light chain variable region (VL) on a separate polypeptide chain; and
(b) a second half antibody comprising in an N- to C-terminal orientation:
(i) a second Fc domain which lacks a Fab domain at its N-terminus, the second Fc domain associated with the first Fc domain to form an Fc heterodimer; and
(ii) a second Fab domain that binds to the target molecule, the second Fab domain comprising a second VH associated with a second VL on a separate polypeptide chain.